

PROSTATE CANCER FOUNDATION *of* AUSTRALIA LIMITED

ABN: 42 073 253 924

AS TRUSTEE FOR PROSTATE CANCER FOUNDATION OF AUSTRALIA

ABN: 31 521 774 656

CONSOLIDATED FINANCIAL REPORT
FOR THE YEAR ENDED 30 JUNE 2016



Prostate Cancer
Foundation of Australia

pcfa.org.au

DIRECTORS' REPORT

Your directors present their report together with the consolidated financial statements of the Group, which comprises Prostate Cancer Foundation of Australia Limited and its controlled entity Prostate Cancer Foundation of Australia ("PCFA") for the year ended 30 June 2016.

Directors

The names of each person who has been a director during the year and to the date of this report are:

Mr Jim Hughes AM

Mr Steve Callister

Emeritus Professor Bruce Armstrong AM

(Appointed 8/12/2015)

Mr Michael Brock

Distinguished Professor Judith Clements

Professor Mark Frydenberg AM

(Appointed 8/10/2015)

Mr Peter Gebert

(Retired from 8/12/2015)

Mr Chris Hall

Mr Peter Haylen

(Appointed 8/12/2015)

Dr David Malouf

(Retired from 8/10/2015)

Professor John Mills AO

(Retired from 8/12/2015)

Mr Bill Munro

Mr John Palmer

Mr Tony Sonneveld OAM

(Retired from 8/12/2015)

Mr Geoff Underwood

(Appointed 8/12/2015)

Mr Ian Wagner

Directors have been in office since the start of the year to the date of this report unless otherwise stated.

Company Secretary

Associate Professor Anthony Lowe BA MA MMath PhD FIAA FIA held the position of Company Secretary at the end of the financial year.

DIRECTORS' REPORT

Principal Activities

The principal activities of PCFA during the 2015/16 financial year were focussed on reducing the impact of prostate cancer on Australian men, their partners, families and the wider community. We did this by:

- Promoting and funding world leading, innovative research into Prostate Cancer
- Implementing awareness and advocacy campaigns and education programs for the Australian community, health professionals and Government; and
- Supporting men and their families affected by prostate cancer through evidence-based information and resources, support groups and Prostate Cancer Specialist Nurses.

PCFA continued the Specialist Nursing Program with funds provided from the Commonwealth of Australia as represented by the Department of Health.

Members Guarantee

In accordance with the company's constitution, each member is liable to contribute \$10 in the event the company is wound up. The total amount members would contribute is \$460.

Operating Result

The operating surplus/ (deficit) of PCFA for the year ended 30 June 2016 amounted to a deficit of \$2,477,441 (2015: deficit \$5,598,802).

Dividends

PCFA is limited by guarantee and is not permitted to pay dividends.

Review of Operations

PCFA's operations for the year resulted in a deficit of \$2,477,441 (2015: deficit \$5,598,802) after the approval of research grants and specialist nursing program totalling \$4.37 million (2014/15 \$11.70 million). PCFA deliberately allocated funds to the Specialist Nursing Program and continued the activities funded by the Australian Government in order to expand the activities that are consistent with PCFA's mission of reducing the impact of prostate cancer on the Australian community.

Significant Changes in State of Affairs

No significant changes to PCFA's state of affairs occurred during the financial year.

After Balance Date Events

No further matters or circumstances have arisen since the end of the financial year which significantly affected or may affect the operations of PCFA, the results of those operations, or state of affairs of PCFA in future financial years.

Future Developments

PCFA expects to maintain the present status and level of operations and hence there are no likely significant developments in PCFA's operations.

Environmental Issues

PCFA's operations are not regulated by any significant environmental regulation under a law of the Commonwealth or of a State or Territory.

Objectives

PCFA's objectives are:

- Be the peak independent body driving research into prostate cancer
- Improve early detection rates
- Be known as the best source for support and information regarding prostate cancer
- Be a sustainable organisation capable of delivering the mandate now and in the future

To achieve these aims PCFA has continued to fund high quality research through its national grants programme, as noted above, promoted and supported the establishment of additional support groups which, nationally, now number 170, and raised awareness of prostate cancer through the production of several new publications and our regular newsletter, all of which are accessible via the PCFA website.

Options

No options over issued shares or interests in PCFA were granted during or since the end of the financial year and there were no options outstanding at the date of this report.

Information on Directors

Mr Jim Hughes AM – National Chairman

GAICD, Snr Assoc, ANZIF

Jim has had a ten year involvement with PCFA. He has held senior positions in the insurance industry throughout Australia over many years and is actively involved in community activities.

He is a Senior Associate of the Australian and New Zealand Institute of Insurance and Finance and a graduate of the Australian Institute of Company Directors.

He is a past lecturer on corporate risk management and business strategy formulation on behalf of the Australian Institute of Company Directors. Jim is a Director of Youi Insurance, Ambooriny Burru Charitable Foundation and KRED Enterprises Charitable Trust. He is also a patron of the Apex Foundation of Australia and a Life Governor of the Apex Clubs of Australia.

Mr Steve Callister – Deputy National Chairman

B.Bus, MBA FCPA, FAICD, FAIM

Steve is Managing Director and Partner of an import wholesale company, dealing with all major retailers in Australia and New Zealand. Former roles include Convenor of St Vincent's Prostate Cancer Support Group, Chairman of the NSW SAC, delegate to the National SAC and Chairman of the NSW Board. Steve became Chairman of PCFA's Marketing and Fundraising Committee of the National Board in May 2009 and National Deputy Chairman in 2015.

Emeritus Professor Bruce Armstrong AM

BMedSc(Hons), MBBS(Hons), DPhil, FRACP, FFAPHM

Bruce Armstrong is internationally recognised for his research into the causes and prevention of cancer, having published over 600 papers in scientific books and journals. His research has included work into trends in PSA testing in Australia and their effects on prostate cancer incidence and mortality, and the effects of diagnosis and treatment of prostate cancer on men's quality of life.

He contributed extensively to the new Australian guidelines for PSA testing and early management of test-detected prostate cancer developed by Prostate Cancer Foundation of Australia and Cancer Council Australia.

Bruce is now retired from full-time employment but continues to contribute actively to research, research translation and aspects of health care as an Emeritus Professor at the University of Sydney and an Adjunct Professor at the University of WA.

He has previously occupied, among others, the roles of Commissioner of Health for WA, Deputy Director of the International Agency for Research on Cancer, Director of the Australian Institute of Health and Welfare, Director of Research and Registers at Cancer Council NSW and Head of the University Of Sydney School Of Public Health.

Bruce was made a Member of the Order of Australia in 1998 for his work in cancer epidemiology and a Fellow of the Australian Academy of Science in 2000.

In 2015 he was listed by Thomson Reuters among some 3,000 other scientists as The World's Most Influential Scientific Minds on the basis of their number of highly cited papers published in 2003 to 2013.

Mr Michael Brock

Michael Brock is a real estate veteran of over 40 years. He has owned his own business since 1982, and is the largest shareholder of Harcourts SA.

He has twice been President of The Real Estate Institute of South Australia, served on the National Board, has conducted over 8000 residential auctions and was the inaugural Auctioneering Champion of the Australian Auctioneering Competition (the only South Australian to win this award).

He has also presented at The National Association of Realtors at a 20,000 delegate Conference in Atlanta USA, and still does presentations around Australia.

His service to the community includes being SA/NT Chairman of PCFA, Chair of the Burnside Hospital Major Fundraising Committee, Chair Sir Donald Bradman Collection Appeal; a Former Board Member of South Australian Housing Trust (now Housing SA), a former Board Member of The Australian Formula One Grand Prix Board (S.A.) and The Motor Sport Board (S.A.), a Life Member of St. Peters Old Collegians Football and Cricket Clubs and Life Member of Real Estate Institute of South Australia.

Distinguished Professor Judith Clements AC

BASc, MASc, PhD (Endocrinology)

Judith is the Scientific Director of the Australian Prostate Cancer Research Centre – Queensland (APCRC-Q), a dedicated prostate cancer research centre and a collaboration between the Institute of Health and Biomedical Innovation, Queensland University of Technology (QUT) and the Princess Alexandra Hospital.

She is based at the new Translational Research Institute on the Princess Alexandra Hospital Biomedical Precinct. Judith is the Chair of the virtual national prostate cancer tissue bank – the Australian Prostate Cancer Bio Resource, an important resource that underpins prostate cancer research nationally, and is co-leader of the Queensland node of the international genetics study for prostate cancer, PRACTICAL.

She is a two-time winner of the Alban Gee Prize from the Urological Society of Australasia, and has also been the recipient of the QUT Vice Chancellor's Award for Research Excellence. She was awarded the Queensland Women in Technology Biotech Outstanding Achievement Award for 2012, and the prestigious title of Distinguished Professor, the only woman in QUT's history, in 2013. She was awarded the Companion of the Order of Australia in 2015.

Professor Mark Frydenberg AM

MBBS FRACS

Professor Mark Frydenberg is a clinical professor in the Department of Surgery, Faculty of Medicine, Monash University; Clinical Chairman, Prostate Cancer Research Group, Department of Anatomy and Developmental Biology, Faculty of Medicine, Monash University and Chairman, Department of Urology, Monash Health, Melbourne, Victoria, Australia.

He is currently the President of the Urological Society of Australia and New Zealand, and was the inaugural chairman, of the Urologic Oncology Special Advisory Group of this organisation. His main research interests are in the area of Urologic Oncology having published greater than 130 papers on clinical, epidemiological and psycho-oncology/survivorship aspects of all major urological cancers, with approximately 10 million dollars in grant funding in urological cancer research over the last 10 years.

This included being the principal investigator for the Victorian Cancer Agency funded CAPTIV collaboration (CAncer of the Prostate Translational research In Victoria).

He has previously held board membership of Andrology Australia and was the inaugural chairman, Clinical Institute of Speciality Surgery, Epworth Healthcare. He is on the Executive committee of the World Urologic Oncology Federation, the Australian representative of the Asia-Pacific Society of Uro-Oncology, and is a regular reviewer for multiple major urologic journals, NHMRC and Prostate Cancer UK.

Mr Chris Hall

B.Comm. (Hons), CA

Chris joined the Board of PCFA in May 2007 as Finance Director. He is a partner at KPMG and having previously been a member of the firm's National Executive Committee and a board member. He was also a member of the Australian Auditing and Assurance Standards board until January 2011.

Mr Peter Haylen

Peter established the law firm, Haylen McKenzie in 1987 and remains a senior partner. He continues to practise, frequently as an advocate in the field of industrial law, succession and insolvency. Peter was diagnosed with prostate cancer in 2010.

He joined Prostate Cancer Foundation of Australia's NSW/ACT State Board in 2011, and was appointed a National Director in 2015. Peter is also a foundation member of Medicins Sans Frontiers, a cricket umpire, former manager of women's cricket teams and is a member of Flags Australia.

Mr Bill Munro

Bill Munro has recently retired from a business career as a company director and merchant banker although remains involved as a strategic planning consultant. He is also a director and committee member of a number of not-for-profit organisations

Bill is Chairman of PCFA in Western Australia and in the past has been Chairman of the Royal West Australian Institute for the Blind, a Director of Homeswest, and a Board member of the WA Theatre Company.

Bill is a Vietnam veteran and maintains his ex-service links through the Returned and Services League and the Royal Australian Regiment Association. He joined the Board of PCFA in Western Australia in 2011 and was appointed Deputy Chairman in 2012.

Mr John Palmer

B.A, B.Sc.App (Building) Class 1 Hons, FAIM, FAIB, MIAA, Chartered Builder, JP.

John is a Past President of the Rotary Club of Lane Cove and a Rotarian of 35 years. In 1997 he was the second Chairman of PCFA.

He is a retired Associate Lecturer University of Technology Sydney. John is a Chartered Builder and the owner and sole director of Building Durability Pty Ltd, T A Taylor (Aust) Pty Ltd and Research & Applied Technologies Pty Ltd.

In 1991 John established a joint venture with and was a Board Member of the TIANAO Building Repair Materials Institute in Tianjin China until 2002.

DIRECTORS' REPORT

Mr Geoff Underwood

Certificate of Business Studies (Real Estate)

Geoff Underwood joined the Victorian Board of PCFA in 2011 and became chairman in 2015. A prostate cancer survivor, his participation with PCFA represents a continuation of service over a long period at local, state and national levels with community groups, industry associations and government committees.

Following national service and duty in Vietnam for which he received a commendation from the Commander of Australian Forces in Vietnam for his "special contribution to Australia's war effort", Geoff worked in State Government from 1971 to 1981 when he moved to private industry. Since then he has run his own consultancies specialising in town planning advice, property development, demographics and urban economics. He is currently Managing Director of Spade Consultants Pty Ltd which offers those specialist services to government and private clients.

Geoff is recognised as a life member of community and industry groups and was awarded in 2015 for his "outstanding contributions to planning in Victoria".

Mr Ian Wagner

Ian resided in Alice Springs for 40 years prior to relocating to the Adelaide Hills town of Mount Barker in December 2013. First becoming involved with the Alice Springs Prostate Cancer Support Group, when diagnosed with Prostate Cancer in 2009.

He was elected to Central Australia Chapter Council in 2012 and as Chairman of the Chapter in 2013. Ian is the Chairman of PCFA's National Support Groups Committee.

Ian was presented with the prestigious PCFA Max Gardner award in 2015 for distinguished service to the Prostate Cancer Foundation of Australia Support Group Network.

Ian's work experience includes General Building and Civil Construction, as Regional Manager, Northern Territory, and Major Masters Sports Event Management. Also a period of Acting Director for the Anglican Church's Welfare Agency, St Marys, in Alice Springs.

His community involvement includes being a past member of several committees; Schools, Sporting organisations etc. and a Government Advisory Board. He has been a member of the Lions Service Clubs for 43 years and is a Life Member of Lions Clubs International.

DIRECTORS' REPORT

Meetings of Directors

During the year, 4 meetings of directors were held.

Attendances by each director were as follows:

DIRECTORS MEETINGS ATTENDED	ELIGIBLE TO ATTEND	NUMBER ATTENDED
Mr Jim Hughes AM	4	4
Mr Steve Callister	4	4
Emeritus Professor Bruce Armstrong AM	2	2
Mr Michael Brock	4	4
Distinguished Professor Judith Clements AC	4	3
Professor Mark Frydenberg AM	4	2
Mr Peter Gebert	2	1
Mr Chris Hall	4	4
Mr Peter Haylen	2	2
Dr David Malouf	1	1
Professor John Mills AO	2	2
Mr Bill Munro	4	4
Mr John Palmer	4	4
Mr Tony Sonneveld OAM	2	2
Mr Geoff Underwood	2	2
Mr Ian Wagner	4	4

DIRECTORS' REPORT

Indemnifying Officers or Auditor

During the financial year, PCFA paid a premium of \$4,400 (2015: \$4,400) to insure the directors and secretaries of the company and its controlled entities.

The liabilities insured are legal costs that may be incurred in defending civil or criminal proceedings that may be brought against the officers in their capacity as officers of entities in the group, and any other payments arising from liabilities incurred by the officers in connection with such proceedings. This does not include such liabilities that arise from conduct involving a wilful breach of duty by the officers or the improper use by the officers of their position or of information to gain advantage for themselves or someone else or to cause detriment to the company. It is not possible to apportion the premium between amounts relating to the insurance against legal costs and those relating to other liabilities.

Proceedings on Behalf of PCFA

No person has applied for leave of Court to bring proceedings on behalf of PCFA or intervene in any proceedings to which PCFA is a party for the purpose of taking responsibility on behalf of PCFA for all or any part of those proceedings. PCFA was not party to any such proceedings during the year.

Auditor's Independence Declaration

A copy of the Auditor's independence declaration as required under Section 60-40 of the Australian Charities and Not-for-Profit Commission (ACNC) Act 2012 is set out on page 8 and forms part of the Directors' Report.

Auditor

PricewaterhouseCoopers continues in office in accordance with section 327 of the Corporations Act 2001.

Signed in accordance with a resolution of the Board of Directors.



Chris Hall

DIRECTOR

Dated this day of 23 September 2016
Sydney, NSW



Auditor's Independence Declaration

As lead auditor for the audit of Prostate Cancer Foundation of Australia Limited for the year ended 30 June 2016, I declare that to the best of my knowledge and belief, there have been:

- (a) No contraventions of the auditor independence requirements of the Corporations Act 2001 in relation to the audit; and
- (b) No contraventions of any applicable code of professional conduct in relation to the audit.

A handwritten signature in black ink, appearing to read 'James McElvogue', written in a cursive style.

James McElvogue

PARTNER

PricewaterhouseCoopers

Sydney
23 September 2016

**CONSOLIDATED STATEMENT OF PROFIT OR LOSS
AND OTHER COMPREHENSIVE INCOME FOR THE
YEAR ENDED 30 JUNE 2016**

	NOTE	2016	2015
		\$	\$
Revenue	4	9,491,980	15,415,388
Administration employee benefit expenses		(1,786,813)	(1,895,987)
Direct fundraising expenses		(2,169,359)	(2,360,538)
Direct support group expenses		(689,914)	(1,024,819)
Research grants & Specialist Nursing Program		(4,366,325)	(11,704,625)
Direct awareness activity expenses		(1,033,720)	(1,153,819)
Project and other administration expenses		(1,921,893)	(2,811,729)
Loss on sale of financial assets		(1,397)	(62,673)
Current year deficit before income tax		(2,477,441)	(5,598,802)
Income tax expense	2 (o)	-	-
Net current year deficit		(2,477,441)	(5,598,802)
<i>Other Comprehensive loss Items that will be reclassified subsequently to profit and loss when specific conditions are met:</i>			
Loss on revaluation of available for sale financial assets		(339)	(8,187)
Total comprehensive income for the year		(2,477,780)	(5,606,989)

The accompanying notes form part of these consolidated financial statements.

**CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2016**

	NOTE	2016	2015
		\$	\$
ASSETS			
CURRENT ASSETS			
Cash and cash equivalents	6	11,529,230	6,493,501
Trade and other receivables	7	1,292,255	10,490,107
Other current assets	8	258,401	273,804
Inventory	9	–	18,668
TOTAL CURRENT ASSETS		13,079,886	17,276,080
NON-CURRENT ASSETS			
Financial assets	10	8,856	63,748
Plant and equipment	11	202,621	213,243
Leasehold Improvements	11	56,194	84,488
TOTAL NON-CURRENT ASSETS		267,671	361,479
TOTAL ASSETS		13,347,557	17,637,559
LIABILITIES			
CURRENT LIABILITIES			
Trade and other payables	12	482,796	897,870
Research grants payable	13	7,867,895	5,571,340
Specialist Nursing Program payable	13	2,330,441	2,249,834
Provisions	14	15,907	61,906
TOTAL CURRENT LIABILITIES		10,697,039	8,780,950
NON-CURRENT LIABILITIES			
Trade and other payables	12	1,311	871
Research grants payable	13	1,707,406	4,141,178
Specialist Nursing Program payable	13	322,850	1,668,480
Provisions	14	84,456	35,202
TOTAL NON-CURRENT LIABILITIES		2,116,023	5,845,731
TOTAL LIABILITIES		12,813,062	14,626,681
NET ASSETS		534,495	3,010,878
EQUITY			
Reserves	15	(8,356)	(9,414)
Retained earnings		542,851	3,020,292
TOTAL EQUITY		534,495	3,010,878

The accompanying notes form part of these consolidated financial statements.

**CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 JUNE 2016**

	RETAINED EARNINGS	ASSET REVALUATION RESERVE	TOTAL
	\$	\$	\$
Balance at 30 June 2014	8,619,094	(63,900)	8,555,194
Total comprehensive loss	(5,598,802)	(8,187)	(5,606,989)
Reserve written back on realisation of financial assets	–	62,673	62,673
Balance at 30 June 2015	3,020,292	(9,414)	3,010,878
Total comprehensive loss	(2,477,441)	(339)	(2,477,780)
Reserve written back on realisation of financial assets	–	1,397	1,397
Balance at 30 June 2016	542,851	(8,356)	534,495

The accompanying notes form part of these consolidated financial statements.

**CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 30 JUNE 2016**

	NOTE	2016	2015
		\$	\$
CASH FLOWS FROM OPERATING ACTIVITIES			
Receipts and contributions from the public and government		18,439,444	8,366,074
Payments to suppliers and employees		(7,745,167)	(7,586,628)
Research grants and Specialist Nursing Program paid		(5,768,565)	(9,690,703)
Interest and other income received		159,084	475,354
Net cash (used in)/generated from operating activities	20	5,084,796	(8,435,903)
CASH FLOWS FROM INVESTING ACTIVITIES			
Proceeds from sale of investments		54,553	71,639
Payments for investments		–	–
Proceeds from sale of plant and equipment		–	13,135
Payments for plant and equipment		(40,656)	(41,840)
Net cash generated from/(used in) investing activities		13,897	42,934
Net increase in cash held		5,098,693	(8,392,969)
Cash at the beginning of the financial year		6,493,501	14,886,470
Cash at the end of the financial year	6	11,592,194	6,493,501

The accompanying notes form part of these consolidated financial statements.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2016

Notes to and Forming Part of the Financial Statements

Note 1: Corporate Information

The financial report of Prostate Cancer Foundation of Australia for the year ended 30 June 2016 was authorised for issue in accordance with a resolution of the directors.

Prostate Cancer Foundation of Australia Limited (the Company) is a company domiciled in Australia, the sole activity of which is to act as the corporate trustee of Prostate Cancer Foundation of Australia (the Trust). The consolidated financial statements as at and for the year ended 30 June 2016 comprise the Company and the Trust, collectively referred to as PCFA. PCFA is a not for profit entity.

The nature of the operations and principal activities of PCFA are described in the Directors' Report.

Note 2: Statement of Significant Accounting Policies

Basis of Preparation

The financial report is a general purpose financial report that has been prepared in accordance with Australian Accounting Standards-Reduced Disclosure Requirements (including Australian Accounting Interpretations), the *Australian Charities and Not-for-Profits Commission Act 2012* and its associated regulations.

Australian Accounting Standards set out accounting policies that the AASB has concluded would result in a financial report containing relevant and reliable information about transactions, events and conditions.

Material accounting policies adopted in the preparation of this financial report are presented below and have been consistently applied unless otherwise stated.

The financial report has been prepared on an accrual basis and is based on historical costs, modified, where applicable, by the measurement at fair value of selected non-current assets and financial assets. All amounts are stated in Australian Dollars and in presenting the financial report are rounded to the nearest dollar.

(a) Revenue

Fundraising proceeds, bequests and donations are accounted for when received and when PCFA is legally entitled to the income.

Interest revenue is recognised on a proportional basis taking into account the interest rates applicable to the financial assets.

All revenue is stated net of the amount of goods and services tax (GST) payable to the Australian Taxation Office.

Revenue from the sale of goods is recognised when control passes to the buyer.

(b) Government Contributions

PCFA will recognise government grants in the Statement of Comprehensive Income on a systematic basis over the period in which PCFA recognises, as expenses, the related costs for which the grants are intended to compensate, provided the condition that specified services are delivered or conditions fulfilled as stated in the funding agreements. These contributions are received on the condition that specified services are delivered or conditions fulfilled. These contributions are recognised at the fair value upon receipt at which time an asset is taken up in the Statement of Financial Position and the revenue recognised in the Statement of Comprehensive Income.

(c) Donations in Kind

Items donated for use are included at the fair value to PCFA where this value can be quantified and a third party is bearing the cost.

No amounts are included in the financial statements for services donated by volunteers.

(d) Expenditure

Expenditure is accounted on an accrual basis and has been classified under headings that aggregate all costs relating to that category. The categories in the consolidated statement of comprehensive income reflect PCFA activities.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2016**

(e) Plant & Equipment

Plant and equipment are measured on the cost basis, less depreciation and impairment losses.

The carrying amount of plant and equipment is reviewed annually by directors to ensure it is not in excess of the recoverable amount from these assets. The recoverable amount is assessed on the basis of the expected net cash flows that will be received from the asset's employment and subsequent disposal. The expected net cash flows have been discounted to their present value in determining their recoverable amounts.

Plant and equipment that have been contributed at no cost, or for nominal cost, are valued at the fair value of the asset at the date it is acquired.

Depreciation

The depreciable amount of all fixed assets is depreciated on a straight line basis over the asset's useful life to PCFA commencing from the time the asset is held ready for use.

Leasehold improvements are depreciated over the unexpired period of the lease.

The useful life applied for each class of depreciable assets is:

Class of Fixed Asset	Useful Lives
Computer equipment	1-5 years
Office furniture and equipment	10-20 years
Leasehold improvement	3-5 years

The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at each balance sheet date. Gains and losses on disposals are determined by comparing proceeds with the carrying amount. These gains or losses are included in the Statement of Comprehensive Income.

(f) Leases

Leases of fixed assets, where substantially all the risks and benefits incidental to the ownership of the asset, but not the legal ownership, are transferred to PCFA are classified as finance leases.

Finance leases, which transfer to PCFA substantially all the risks and benefits incident to ownership of the leased item, are capitalised, recording an asset and a liability equal to the present value of the minimum lease payments, including any guaranteed residual values.

Leased assets are depreciated on a straight line basis over their estimated useful lives where it is likely that PCFA will obtain ownership of the asset. Lease payments are allocated between the reduction of the lease liability and the lease interest expense for the period.

Lease payments for operating leases, where substantially all the risks and benefits remain with the lessor, are charged as expenses on a straight-line basis over the lease term.

Lease incentives under operating leases are recognised as a liability and amortised on a straight-line basis over the life of the lease term

(g) Inventories

Inventories of goods purchased for resale are valued at the lower of cost or net realisable value.

(h) Financial Instruments

Initial recognition and measurement

Financial assets and financial liabilities are recognised when PCFA becomes a party to the contractual provisions of the instrument. For financial assets, this is equivalent to the date that PCFA commits itself to either purchase or sell the asset (i.e. trade accounting is adopted). Financial instruments are initially measured at fair value plus transactions costs except where the instrument is classified "at fair value through profit or loss" in which case transaction costs are expensed to profit or loss immediately.

Classification and subsequent measurement

Financial instruments are subsequently measured at fair value, amortised cost using the effective interest rate method or cost. Fair value represents the amount for which an asset could be exchanged or a liability settled, between knowledgeable, willing parties. Where available, quoted prices in an active market are used to determine fair value. In other circumstances, valuation techniques are adopted.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2016**

Amortised cost is calculated as:

- i. the amount at which the financial asset or financial liability is measured at initial recognition
- ii. less principal repayments;
- iii. plus or minus the cumulative amortisation of the difference, if any, between the amount initially recognised and the maturity amount calculated using the effective interest method; and
- iv. less any reduction for impairment.

The effective interest rate method is used to allocate interest income or interest expense over the relevant period and is equivalent to the rate that exactly discounts estimated future cash payments or receipts (including fees, transaction costs and other premiums or discounts) through the expected life (or, when this cannot be reliably predicted, the contractual term) of the financial instrument to the net carrying amount of the financial asset or financial liability. Revisions to expected future net cash flows will necessitate an adjustment to the carrying value with a consequential recognition of an income or expense in profit or loss.

- (i) **Financial assets at fair value through profit or loss**
Financial assets are classified at 'fair value through profit or loss' when they are held for trading for the purpose of short-term profit taking, or where they are derivatives not held for hedging purposes, or when they are designated as such to avoid an accounting mismatch or to enable performance evaluation where a group of financial assets is managed by key management personnel on a fair value basis in accordance with a documented risk management or investment strategy. Such assets are subsequently measured at fair value with changes in carrying value being included in profit or loss.
- (ii) **Loans and receivables**
Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market and are subsequently measured at amortised cost.
- (iii) **Held-to-maturity investments**
Held-to-maturity investments are non-derivative financial assets that have fixed maturities and fixed or determinable payments, and it is PCFA's intention to hold these investments to maturity. They are subsequently measured at amortised cost.

(iv) **Available-for-sale financial assets**

Available-for-sale financial assets are non-derivative financial assets that are either not capable of being classified into other categories of financial assets due to their nature, or they are designated as such by management. They comprise investments in the equity of other entities where there is neither a fixed maturity nor fixed or determinable payments.

Available-for-sale financial assets are classified as non-current assets.

(v) **Financial liabilities**

Non-derivative financial liabilities (excluding financial guarantees) are subsequently measured at amortised cost.

Fair Value

Fair value is determined based on current bid prices for all quoted investments. Valuation techniques are applied to determine the fair value of all unlisted securities, including recent arm's length transactions, reference to similar instruments and option pricing models.

Impairment

At each reporting date, PCFA assesses whether there is objective evidence that a financial instrument has been impaired. In the case of available-for-sale financial instruments, a prolonged decline in the value of the instrument is considered to determine whether impairment has arisen. Impairment losses are recognised in the Statement of Comprehensive Income.

Derecognition

Financial assets are derecognised where the contractual rights to receipt of cash flows expires or the asset is transferred to another party whereby PCFA no longer has any significant continuing involvement in the risks and benefits associated with the asset. Financial liabilities are derecognised where the related obligations are either discharged, cancelled or expired. The difference between the carrying value of the financial liability, which is extinguished or transferred to another party and the fair value of consideration paid including the transfer of non-cash assets or liabilities assumed is recognised in profit or loss.

(i) **Impairment of Assets**

At each reporting date, PCFA reviews the carrying values of its tangible and intangible assets to determine whether there is any indication that those assets have been impaired. If such an indication exists, the recoverable amount of the asset, being the higher of the asset's fair value less costs to sell and value in use, is compared to the asset's carrying value. Any excess of the asset's carrying value over its

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2016

recoverable amount is expensed to the Statement of Comprehensive Income.

Where the future economic benefits of the asset are not primarily dependent upon on the assets ability to generate net cash inflows and when PCFA would, if deprived of the asset, replace its remaining future economic benefits, value in use is depreciated cost of an asset.

Where it is not possible to estimate the recoverable amount of an assets class, PCFA estimates the recoverable amount of the cash-generating unit to which the class of assets belong.

Where an impairment loss on a revalued asset is identified, this is debited against the revaluation reserve in respect of the same class of asset to the extent that the impairment loss does not exceed the amount in the revaluation reserve for that same class of asset.

(j) Research Grants and Specialist Nursing Program

Research grants are expensed through the Statement of Comprehensive Income and recognised as a liability when PCFA has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

Specialist Nursing Program payments are expensed through the Statement of Comprehensive Income and recognised as a liability when PCFA has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

It is considered that upon PCFA National Board approval of the research grants or placement application and notification of success to the applicant organisation, PCFA is constructively obliged to fund the contract whereby an economic benefit will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

(k) Employee Benefits

Employee benefits comprise wages and salaries, annual, sick and long service leave, and contributions to employee superannuation funds.

Provision is made for PCFA's liability for employee benefits arising from services rendered by employees to balance sheet date. Employee benefits, expected to be settled within one year, together with benefits arising from wages, salaries and annual leave which may be settled after one year, have been measured at

the amounts expected to be paid when the liability is settled. Other employee benefits, payable later than one year, have been measured at the net present value.

Contributions are made by PCFA to employee superannuation funds and are charged as expenses when incurred. PCFA has no further obligation to pay further contributions to these funds if the funds do not hold sufficient assets to pay all employees benefits relating to employee service in current and prior periods. Liabilities for sick leave are recognised when the leave is taken and are measured at the rates paid.

(l) Cash and Cash Equivalents

Cash and cash equivalents in the consolidated statement of financial position include cash at bank, cash on hand, short-term deposits held with banks with an original maturity of six months or less that are readily convertible to known amounts of cash and which are subject to insignificant risk of changes in value, other short-term highly liquid investments and bank overdrafts.

For the purposes of the statement of cash flow, cash and cash equivalents consist of cash and cash equivalents as defined above, net of any outstanding bank overdrafts.

(m) Accounts Receivable and other debtors

Accounts receivable which are expected to be collected within 12 months are classified as current assets. All other receivables are classified as non-current assets. Accounts receivable are initially recognised at fair value.

Collectability of accounts receivable is reviewed on an ongoing basis. Amounts that are known to be uncollectible are written off when identified.

(n) Goods and Services Tax

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Taxation Office. In these circumstances the GST is recognised as part of the cost of acquisition of the asset or as part of an item of the expense. Receivables and payables in the Balance Sheet are shown inclusive of GST. The amount of GST recoverable from or payable to the ATO is included with other receivables or payables in the Statement of Financial Position. Cash flows are presented in the Statement of Cash Flows on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2016**

(o) Income Tax

No provision for income tax has been made as PCFA is a charitable institution for the purposes of Australian taxation legislation and therefore exempt from income tax under Division 50 of the *Income Tax Assessment Act 1997*.

(p) Provisions

Provisions are recognised when PCFA has a legal or constructive obligation, as a result of past events, for which it is probable that an outflow of economic benefits will result and that outflow can be reliably measured. Provisions recognised represent the best estimate of the amounts required to settle the obligation at reporting date.

(q) Comparative Figures

Where required by Accounting Standards, comparative figures have been adjusted to conform with changes in presentation for the current financial year.

(r) Accounts payable and other payables

Accounts payable and other payables represent liabilities outstanding at the end of the reporting period for goods and services received by PCFA during the financial year which remain unpaid. The balance is recognised as a current liability with the amounts normally paid within 30 days of recognition of the liability. The carrying amount of the payables is deemed to reflect fair value.

(s) Critical Accounting Estimates and Judgements

The directors evaluate estimates and judgements incorporated into the financial report based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both externally and within PCFA.

Key Estimates – Impairment

PCFA assesses impairment at each reporting date by evaluating conditions specific to PCFA that may be indicative of impairment triggers. Recoverable amounts of relevant assets are reassessed using value-in-use calculations which incorporate various key assumptions.

Key judgements – Available-for-sale investments

PCFA maintains a portfolio of managed funds with a carrying value of \$3,200 at reporting date. Should investment prices decline in value for an extended period of time, PCFA has determined that such investments will be considered for impairment in the future.

(t) Basis of Consolidation

Subsidiaries are entities controlled by the Group. The consolidated financial statements incorporate the assets and liabilities of all subsidiaries as at 30 June and results for the year then ended. Intragroup balances and transactions, and any unrealized income and expenses arising, are eliminated in preparing the consolidated financial statements.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2016**

Note 3: Fundraising Appeals Conducted During the Financial Year

The following disclosures for the current period are included to comply with the *Australian Charities and Not-for-Profit Commission Act 2012*.

During the financial year PCFA raised funds primarily through:

- Solicited corporate and general donations;
- Gifts and bequests; and
- Charity events such as Movember

RESULTS FROM FUNDRAISING APPEALS	2016	%	2015	%
	\$		\$	
Gross income from fundraising and donations	9,318,670		14,504,071	
Total cost of fundraising	(2,169,359)	23%	(2,360,538)	16%
Net income after fundraising costs	7,149,311	77%	12,143,533	84%
Total income	9,491,980		15,415,388	
Total expenditure	11,969,421		21,014,190	
Total payments to support services, research grants and specialist nursing service program, awareness activities, plus projects	6,456,184		14,690,912	
Payments to support services, research grants and specialist nursing service program, awareness activities, plus projects as a percentage of total income	68%		95%	
Payments to support services, research grants and specialist nursing service program, awareness activities, plus projects as a percentage of total expenditure	54%		70%	

Further information on the application of the net surplus from fundraising and other income is contained in the Statement of Comprehensive Income and the Statement of Cash Flows.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2016**

Note 4: Revenue and Other Income

	2016	2015
	\$	\$
Revenue from government and other grants	753,750	2,333,350
Fundraising revenue:		
– Donations	483,382	578,352
– Corporate donations	1,249,516	949,609
– Major gifts	816,513	1,087,635
– Direct mail	921,544	836,305
– Movember	–	4,150,000
– Major events	4,720,236	4,166,684
– Trusts and foundations	372,532	397,280
– Merchandise sales	1,197	4,856
Total fundraising revenue	8,564,920	12,170,721
Other revenue	13,407	180,991
Interest and dividends	159,903	281,518
Donations in kind	–	448,808
Total other income	173,310	911,317
Total revenue	9,491,980	15,415,388

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2016**

Note 5: Net Deficit for the Year

	2016	2015
	\$	\$
Net deficit for the year has been determined after the following expenses:		
Project – Specialist Nursing Program administration	192,245	462,686
Project – Supporting men with prostate cancer through evidence-based resources and support	–	202,030
Project – Prostate Cancer Rural Education Road Show	–	90,941
Project – Prostate Cancer Survivorship Research Centre	124,661	83,236
Project – PSA Testing Guidelines	125,969	417,307
Project – iPad App Development	24,691	14,135
Depreciation		
– Furniture and equipment	49,085	47,781
– Leasehold Improvements	28,294	33,291
Employee benefits expense	3,025,602	3,421,331
Including Key management personnel compensation	247,818	237,594
Auditor Remuneration		
– Audit services	53,949	49,950
Donation to Prostate Cancer Foundation of New Zealand	9,477	28,000

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2016**

Note 6: Cash and Cash Equivalents

	2016	2015
	\$	\$
CURRENT		
Cash at bank	3,265,894	1,723,007
Cash on hand	1,179	2,154
Term deposits	8,262,157	4,768,340
	11,529,230	6,493,501

Reconciliation to cash flow statement

The above figures reconcile to the amount of cash shown in the statement of cash flows at the end of the financial year as follows:

	2016	2015
	\$	\$
Balances as above	11,529,230	6,493,501
Other deposits (see note 8 below)	62,964	-
Balances per statement of cash flows	11,592,194	6,493,501

Note 7: Accounts Receivable and Other Debtors

	2016	2015
	\$	\$
CURRENT		
Accounts receivable	179,281	275,334
Movember income receivable	1,061,300	9,400,000
Department of Health receivable	-	740,500
Interest receivable	20,107	5,880
GST receivable	31,567	68,393
	1,292,255	10,490,107

Note 8: Other Current Assets

	2016	2015
	\$	\$
Prepayments	195,437	256,594
Other deposits	62,964	17,210
	258,401	273,804

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2016**

Note 9: Inventory on Hand

	2016	2015
	\$	\$
CURRENT		
Inventory (at cost)	-	18,668

Note 10: Financial Assets

	2016	2015
	\$	\$
NON-CURRENT		
<i>Available-for-sale financial instruments:</i>		
Managed investment portfolio	3,200	58,092
	3,200	58,092
<i>Held to Maturity financial instruments:</i>		
Rental deposits	5,656	5,656
	8,856	63,748

Available-for-sale financial assets comprise of investments in managed funds and listed trusts and listed shares. There are no fixed returns or fixed maturity dates attached to these investments. A gain or loss on an available-for-sale financial asset is recognised directly in equity, through the statement of changes in equity, except for impairment losses and foreign exchange gains and losses, until the financial asset is derecognised, at which time the cumulative gain or loss previously recognised in equity shall be recognised in profit or loss. PCFA does not hold these assets for trading or for short term profit making.

Held to maturity financial assets are comprised of bank deposits held.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2016**

Note 11: Plant and Equipment and Leasehold Improvements

	2016	2015
	\$	\$
Plant and equipment		
At cost	463,622	427,514
Less accumulated depreciation	(261,001)	(214,271)
Total plant and equipment	202,621	213,243
Leasehold Improvements		
At cost	219,860	219,860
Less accumulated depreciation	(163,666)	(135,372)
Total leasehold improvements	56,194	84,488

MOVEMENTS IN CARRYING AMOUNTS	PLANT AND EQUIPMENT	LEASEHOLD IMPROVEMENT
2015	\$	\$
Balance at the beginning of the year	233,620	117,779
Additions at cost	41,840	–
Disposals at cost	(18,605)	–
Depreciation written off on disposal	4,169	–
Depreciation expense	(47,781)	(33,291)
Carrying amount at end of year	213,243	84,488
2016		
Balance at the beginning of the year	213,243	84,488
Additions at cost	40,656	–
Disposals at cost	(4,549)	–
Depreciation written off on disposal	2,356	–
Depreciation expense	(49,085)	(28,294)
Carrying amount at end of year	202,621	56,194

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2016**

Note 12: Accounts Payable and Other Payables

	2016	2015
	\$	\$
Accounts payable and accruals	283,790	661,759
Short-term employees benefits (Annual Leave)	200,317	236,982
	484,107	898,741
<i>Financial liabilities at amortised cost classified as trade and other payables.</i>		
Accounts payable and other payables		
– Total current	482,796	897,870
– Total non-current	1,311	871
	484,107	898,741
Less short term employee benefits	(200,317))	(236,982)
Financial liabilities as trade and other payables	283,790	661,759

Note 13: Research Grants and Specialist Nursing Program Payable

	2016	2015
	\$	\$
CURRENT		
Research grants payable	7,867,895	5,571,340
Specialist Nursing Program payable	2,330,441	2,249,834
NON CURRENT		
Research grants payable	1,707,406	4,141,178
Specialist Nursing Program payable	322,850	1,668,480
	12,228,592	13,630,832

Research grants payable relate to 27 (2015: 31) approved applications to which PCFA is presently committed. These will be paid over the next 4 financial years according to the agreed letters of offer.

Specialist Nursing Program payable is based on funds received from or committed by the Federal Government via the Department of Health during the 2015/16 financial year. Contracts have been awarded to provide nurses in hospitals at various locations around Australia and funds will be set aside for evaluation of the program. These funds are to be expended over several years.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2016**

Note 14: Provisions

	2016	2015
	\$	\$
Long service leave	76,413	21,797
Nursing education	10,544	46,110
Lease incentive	13,406	29,201
	100,363	97,108
Provisions		
– Current	15,907	61,906
– Non current	84,456	35,202
	100,363	97,108

2016	LONG SERVICE LEAVE	NURSING EDUCATION	LEASE INCENTIVE
	\$	\$	\$
Analysis of Total Provisions			
Opening balance at 1 July	21,797	46,110	29,201
Additional provisions raised during year	69,648	–	–
Amounts used	(15,032)	(35,566)	(15,795)
Balance at 30 June	76,413	10,544	13,406

Provision for long-term employee benefits

A provision has been recognised for employee entitlements relating to long service leave. In calculating the present value of future cash flows in respect of long service leave, the probability of long service leave being taken is based on historical data. The measurement and recognition criteria relating to employee benefits have been included in Note 2 to this report.

Provision for Nursing education

A provision has been recognised for amounts provided for education purposes for nurses. These claims are expected to be settled in the next financial year. The provision is based on funds received from an endowment.

Provision for Lease incentive

The company entered into an operating lease for PCFA's Sydney headquarters on 1 January, 2011 for a period of 5 years. PCFA received a rent free incentive of \$104,330 in the form of rent, outgoings and parking. This incentive is amortised over the life of the lease. The option to renew the lease for a further period of 5 years has been exercised but no further lease incentive has been received.

The company entered into a new operating lease for PCFA's Melbourne office on 6 January, 2014 for a period of 5 years. PCFA received a rent free incentive of \$26,812 in the form of rent, outgoings and parking. This incentive will be amortised over the life of the lease.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2016**

Note 15: Reserves

Asset Revaluation Reserve

This reserve records the revaluation of financial assets classified as available-for-sale, which is the difference between the asset's carrying value and market value at balance sheet date.

	2016	2015
	\$	\$
Opening balance 1 July	(9,414)	(63,900)
Revaluation of available for sale assets	(339)	(8,187)
Reserve written back on realisation of financial assets	1,397	62,673
Balance 30 June	(8,356)	(9,414)

Note 16: Capital and Leasing Commitments

(a) Operating lease commitments

	2016	2015
	\$	\$
<i>Non-cancellable operating leases contracted for but not capitalised in the financial statements.</i>		
Payable – minimum lease payments		
– not later than 12 months	372,422	346,904
– later than 12 months but not later than 5 years	954,381	1,137,434
– greater than 5 years	575	118,037
	1,327,378	1,602,375

The property lease commitments are non-cancellable operating leases contracted for but not capitalised in the financial statements within a three year term. No capital commitments exist in regards to the operating lease commitments at year-end. Increase in lease commitments are in line with the lease agreements at an average increase of 4% upon each anniversary date. PCFA is able to renew the term of operating leases for a further three years upon termination of the current lease period.

(b) Capital commitments

PCFA have no capital commitments that require disclosure in this report.

Note 17: Contingent Liabilities and Assets

PCFA has a bank guarantee at 30 June 2016 for the performance of certain office lease commitments amounting to \$158,728 (2015: \$158,728).

PCFA has contingent assets totalling \$3,750,000 (2015: \$0) in relation to funding agreement receivable from the Movember Foundation.

PCFA has contingent assets totalling \$1,624,000 (2015: \$2,364,500) in relation to funding agreement receivable from the Department of Health and Aging.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2016**

Note 18: Events After Balance Sheet Date

No matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of PCFA, the results of those operations, or the state of affairs of PCFA in subsequent financial years.

Note 19: Related Parties and Related Party Transactions

Directors' compensation

The directors act in an honorary capacity and receive no compensation for their services.

Transactions with related entities

During the year, funding for the 'new concept grant' undertaken by the Translational Research Institute in Queensland University of Technology was approved. This project commencing 1 January will be funded for a year with a total approved budget of \$99,732 (GST inclusive). The purpose of this project is to determine whether KLK14 is a novel therapeutic target in muscle wasting induced by androgen deprivation therapy. Distinguished Professor Judith Clements, Director of Prostate Cancer Foundation of Australia, is also a principal investigator for this project.

It is noted that in the prior year, funding for the 'APCC BioResource grant' undertaken by the Translational Research Institute in Queensland University of Technology was approved. This project was funded for a year with a total approved budget of \$200,000 (GST inclusive). The purpose of this project is to support research for the APCC BioResource. Distinguished Professor Judith Clements, Director of Prostate Cancer Foundation of Australia, is also a principal investigator for this project.

All PCFA research grants are peer reviewed by independent expert advisory panels and are awarded on the basis of scientific merit.

No other amounts are payable to or receivable from director related entities at the reporting date.

Note 20: Cash Flow Information

Reconciliation of cashflow from operations with (deficit)/surplus from ordinary activities after income tax.

	2016	2015
	\$	\$
(Deficit)/surplus from ordinary activities	(2,477,441)	(5,598,802)
<i>Non-cash flows</i>		
Loss on Sale of Financial Assets	1,397	62,673
Loss on Sale of plant and equipment	2,193	1,301
Depreciation	77,379	81,072
<i>Changes in assets and liabilities</i>		
Decrease/(Increase) in receivables and other assets	9,197,852	(4,942,630)
Decrease/(Increase) in other current assets	78,367	(24,770)
Increase in inventory	18,668	13,429
Decrease/(Increase) in nursing program & grants payable	(1,402,240)	2,013,922
Increase in trade and other payables	(414,634)	(10,515)
Decrease/(Increase) in provisions	3,255	(31,583)
	5,084,796	(8,435,903)

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2016**

Note 21: Foundation Details

The registered office and principal place of business of PCFA is:

Level 3, 39-41 Chandos Street
St Leonards, New South Wales, 2065

Note 22: Parent Entity Financial Information

The individual financial statements for the parent entity show the following aggregate amounts:

	2016	2015
	\$	\$
Balance Sheet	-	-
Current Assets	-	-
Total Assets	-	-
Current Liabilities	-	-
Total Liabilities	-	-
Shareholders' Equity	-	-
Profit or Loss for the year	-	-
Total Comprehensive Income	-	-

Prostate Cancer Foundation of Australia Limited (ABN 42 073 253 924), a company limited by guarantee, is the corporate trustee for its only controlled entity, Prostate Cancer Foundation of Australia (ABN 31 521 774 656).

Prostate Cancer Foundation of Australia Limited is incorporated under the *Corporations Act 2001*. If it is wound up, the constitution states that each member is required to contribute a maximum of \$10 each towards meeting any outstanding and obligations of PCFA. As at 30 June 2016 the number of members was 46 (2015: 76)

DIRECTORS' DECLARATION

The directors of PCFA declare that:

1. the consolidated financial statements and notes, as set out on pages 11 to 34, are in accordance with the *Australian Charities and Not-for-Profits Commission Act 2012* including:
 - (a) complying with Australian Accounting Standards-Reduced Disclosure Requirements and the Australian Charities and Not-for-Profit Commission Regulation 2013; and
 - (b) giving a true and fair view of the financial position as at 30 June 2016 and of the performance for the year ended on that date of PCFA.
2. in the directors' opinion there are reasonable grounds to believe that PCFA will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors.



Chris Hall
DIRECTOR

Dated this day of 23 September 2016
Sydney, NSW



Independent auditor's report to the members of Prostate Cancer Foundation of Australia Limited

Report on the financial report

We have audited the accompanying financial report of Prostate Cancer Foundation of Australia Limited (the company), which comprises the consolidated statement of financial position as at 30 June 2016, the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the year ended on that date, a summary of significant accounting policies, other explanatory notes and the directors' declaration for Prostate Cancer Foundation of Australia Limited (the consolidated entity). The consolidated entity comprises the company and the entities it controlled at year's end or from time to time during the financial year.

Directors of the company responsibility for the financial report

The directors of the company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards – Reduced Disclosure Requirements and the *Australian Charities and Not-for-profits Commission Act 2012* for such internal control as the directors of the company determine is necessary to enable the preparation of the financial report that is free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express an opinion on the financial report based on our audit. We conducted our audit in accordance with Australian Auditing Standards. Those standards require that we comply with relevant ethical requirements relating to audit engagements and plan and perform the audit to obtain reasonable assurance whether the financial report is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial report. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial report, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the consolidated entity's preparation and fair presentation of the financial report in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the directors of the company, as well as evaluating the overall presentation of the financial report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Basis for Qualified Opinion

Cash from donations and other fundraising activities are a significant source of revenue for the Company. The Company's directors have determined that it is impracticable to establish control over the collection of revenue from these sources prior to entry into its financial records. Accordingly, as the evidence available to us regarding revenue from cash donations and other fundraising activities was limited, our audit procedures with respect to revenue from these sources had to be restricted to the amounts recorded in the Company's financial records. As a result, we are unable to express an opinion as to whether revenue from cash donations and other fundraising activities is complete.

Qualified Opinion

In our opinion, except for the possible effects of the matter described in the Basis for Qualified Opinion paragraph, the financial report of Prostate Cancer Foundation of Australia Limited is in accordance with the Australian Charities and Not-for-profits Commission 2012, including:

- (a) gives a true and fair view of the consolidated entity's financial position as at 30 June 2016 and of its performance for the year ended on that date; and
- (b) complies with Australian Accounting Standards – Reduced Disclosure Requirements.



Matters relating to the electronic presentation of the audited financial report

This auditor's report relates to the financial report of Prostate Cancer Foundation of Australia Limited (the company) for the year ended 30 June 2016 included on Prostate Cancer Foundation of Australia Limited's web site. The company's directors are responsible for the integrity of Prostate Cancer Foundation of Australia Limited's web site. We have not been engaged to report on the integrity of this web site. The auditor's report refers only to the financial report named above. It does not provide an opinion on any other information which may have been hyperlinked to/from the financial report. If users of this report are concerned with the inherent risks arising from electronic data communications they are advised to refer to the hard copy of the audited financial report to confirm the information included in the audited financial report presented on this web site.

A handwritten signature in black ink, appearing to read 'Dimitrios Lysas', written over a light blue horizontal line.

PricewaterhouseCoopers

A handwritten signature in black ink, appearing to read 'James McElvogue', written over a light blue horizontal line.

James McElvogue
PARTNER

Sydney
23 September 2016



**Prostate Cancer
Foundation of Australia**

Prostate Cancer Foundation of Australia
Level 3, 39-41 Chandos Street
St Leonards NSW 2065

pcfa.org.au

Follow us on:   

[facebook.com/pcfa1](https://www.facebook.com/pcfa1)

twitter.com/pcfa

[youtube.com/pcfaweb](https://www.youtube.com/pcfaweb)